Arcturus Therapeutics Holdings Inc.
Financials
Valuation Metrics
Arcturus Therapeutics Holdings Inc.'s Market Cap is $270M. At end of 2025 it was $168M. Ranked #2895 of 3,118 in US market (top 93%), #1303 of 1,474 on NASDAQ (top 88%), #233 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $270M | US#2,895/3,118 Sec#233/265 |
| Revenue | $24M | US#2,779/3,118 Sec#158/265 |
| Net Income | $-93M | US—/3,118 Sec—/265 |
| Total Assets | $224M | US#2,965/3,118 Sec#238/265 |
| Net Assets | $172M | US#2,706/3,118 Sec#197/265 |
| Employees | 109 | US#2,596/3,118 Sec#170/265 |
| Value | ||
| P/B | 1.57x | US#1,156/3,118 Sec#55/265 |
| P/S | 11.33x | US#2,778/3,118 Sec#128/265 |
| FCF Yield | -27.10% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -54.29% | US#2,689/3,118 Sec#162/265 |
| ROA | -41.58% | US#2,946/3,118 Sec#194/265 |
| Op. Margin | -433.36% | US#2,775/3,118 Sec#151/265 |
| Revenue Growth | -79.07% | US#2,713/3,118 Sec#172/265 |
| Financial Health | ||
| Debt Ratio | 30.56% | US#345/3,118 Sec#106/265 |
| Total Debt | $23M | US#2,718/3,118 Sec#182/265 |
| FCF | $-73M | US#2,579/3,118 Sec#128/265 |
| Cash | $191M | US#1,767/3,118 Sec#112/265 |
| Current Ratio | 5.88x | US#397/3,118 Sec#124/265 |
| Performance | ||
| 1Y Return | -4.86% | US#1,342/3,118 Sec#119/265 |
| 1M Return | -27.21% | US#2,789/3,118 Sec#224/265 |
| From 52W High | -47.19% | US#2,291/3,118 Sec#163/265 |
| 1Y MDD | -43.98% | US#2,015/3,118 Sec#128/265 |
| Trading | ||
| Volume | 712,961 shares | US#1,361/3,118 Sec#124/265 |
| Trading Value | $7M | US#2,134/3,118 Sec#163/265 |
| Per Share | ||
| EPS | $-3.28 | US—/3,118 Sec—/265 |
| BPS | $6.04 | US#2,185/3,118 Sec#109/265 |
Company Info
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.